Brain iron deposition analysis using susceptibility weighted imaging and its association with body iron level in patients with mild cognitive impairment

Gao,Lili; Jiang,Zhihong; Cai,Zhaocheng; Cai,Ming; Zhang,Qing; Ma,Yingying; Li,Guoliang; Zhao,Fengzhu; Ma,Qiang

doi:10.3892/mmr.2017.7668

Brain iron deposition analysis using susceptibility weighted imaging and its association with body iron level in patients with mild cognitive impairment

Authors:
- Lili Gao
- Zhihong Jiang
- Zhaocheng Cai
- Ming Cai
- Qing Zhang
- Yingying Ma
- Guoliang Li
- Fengzhu Zhao
- Qiang Ma
View Affiliations

Affiliations: Department of Neurology, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning 116000, P.R. China, Department of Radiology, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning 116000, P.R. China
Published online on: September 29, 2017 https://doi.org/10.3892/mmr.2017.7668
Pages: 8209-8215
Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to analyze brain and body iron levels among patients with mild cognitive impairment (MCI), Alzheimer's disease (AD), and normal controls (NCs). A total of 90 participants (30 MCI, 30 AD, 30 NC) were enrolled. Brain iron content was quantified using susceptibility weighted imaging (SWI). Phase values were used to calculate bilateral iron content in the hippocampus (HP), substantia nigra, red nucleus (RN), dentate nucleus (DN), caudate nucleus (CN), globus pallidus (GP), putamen (PUT), frontal white matter, temporal cortex (TC), and parietal cortex. Body iron indices, including serum iron, serum transferrin, ferritin and total iron binding capacity, were measured. Phase values of the left (L)‑DN, L‑CN, and bilateral PUT in the MCI group were significantly lower compared with NC group. Phase values of the right (R)‑RN, bilateral DN, and bilateral PUT in the AD group were significantly lower compared with the MCI group. Phase values of the bilateral HP, DN, RN, CN, GP, PUT, and L‑TC in the AD group were significantly lower compared with the NC group. Serum ferritin levels in the MCI and AD groups were significantly lower compared with the NC group. Only serum iron in the AD group was positively associated with iron content in the R‑HP. Brain iron deposition and body iron levels both increased in MCI and AD patients, however, excessive brain iron accumulation may have no association with body iron level. SWI was particularly effective at recognizing the presence of brain iron in the MCI and AD groups.

View Figures

View References

1	Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, et al: Toward defining the reclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzhermer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7:280–292. 2011. View Article : Google Scholar : PubMed/NCBI
2	Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, et al: The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7:270–279. 2011. View Article : Google Scholar : PubMed/NCBI
3	McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, et al: The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7:263–269. 2011. View Article : Google Scholar : PubMed/NCBI
4	Petersen RC: Mild cognitive impairment. Continuum (Minneap Minn). 22:404–418. 2016.PubMed/NCBI
5	Ota K, Oishi N, Ito K and Fukuyama H; SEAD-J Study Group, : Alzheimer's Disease Neuroimaging Initiative: Effects of imaging modalities, brain atlases and feature selection on prediction of Alzheimer's disease. J Neurosci Methods. 256:168–183. 2015. View Article : Google Scholar : PubMed/NCBI
6	Goodman L: Alzheimer's disease; a clinico-pathologic analysis of twenty-three cases with a theory on pathogenesis. J Nerv Ment Dis. 118:97–130. 1953. View Article : Google Scholar : PubMed/NCBI
7	Honda K, Casadesus G, Petersen RB, Perry G and Smith MA: Oxidative stress and redox-active iron in Alzheimer's disease. Ann N Y Acad Sci. 1012:179–182. 2004. View Article : Google Scholar : PubMed/NCBI
8	Chamberlain R, Reyes D, Curran GL, Marjanska M, Wengenack TM, Poduslo JF, Garwood M and Jack CR Jr: Comparison of amyloid plaque contrast generated by T2-weighted, T2*-weighted, and susceptibility-weighted imaging methods in transgenic mouse models of Alzheimer's disease. Magn Reson Med. 61:1158–1164. 2009. View Article : Google Scholar : PubMed/NCBI
9	Zhou XX, Qin HL, Li XH, Huang HW, Liang YY, Liang XL and Pu XY: Characterizing brain mineral deposition in patients with Wilson disease using susceptibility-weighted imaging. Neurol India. 62:362–366. 2014. View Article : Google Scholar : PubMed/NCBI
10	Crespo ÂC, Silva B, Marques L, Marcelino E, Maruta C, Costa S, Timóteo A, Vilares A, Couto FS, Faustino P, et al: Genetic and biochemical markers in patients with Alzheimer's disease support a concerted systemic iron homeostasis dysregulation. Neurobiol Aging. 35:777–785. 2014. View Article : Google Scholar : PubMed/NCBI
11	Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG and Kokmen E: Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol. 56:303–308. 1999. View Article : Google Scholar : PubMed/NCBI
12	Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, et al: Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol. 6:734–746. 2007. View Article : Google Scholar : PubMed/NCBI
13	Hallgren B and Sourander P: The effect of age on the non-haemin iron in the human brain. J Neurochem. 3:41–51. 1958. View Article : Google Scholar : PubMed/NCBI
14	Lan AP, Chen J, Chai ZF and Hu Y: The neurotoxicity of iron, copper and cobalt in Parkinson's disease through ROS-mediated mechanisms. Biometals. 29:665–678. 2016. View Article : Google Scholar : PubMed/NCBI
15	Wu Y, Passananti M, Brigante M, Dong W and Mailhot G: Fe(III)-EDDS complex in Fenton and photo-Fenton processes: From the radical formation to the degradation of a target compound. Environ Sci Pollut Res Int. 21:12154–12162. 2014. View Article : Google Scholar : PubMed/NCBI
16	Connor JR, Menzies SL, St Martin SM and Mufson EJ: A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J Neurosci Res. 31:75–83. 1992. View Article : Google Scholar : PubMed/NCBI
17	Grundke-Iqbal I, Fleming J, Tung YC, Lassmann H, Iqbal K and Joshi JG: Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia. Acta Neuropathol. 81:105–110. 1990. View Article : Google Scholar : PubMed/NCBI
18	Liu B, Moloney A, Meehan S, Morris K, Thomas SE, Serpell LC, Hider R, Marciniak SJ, Lomas DA and Crowther DC: Iron promotes the toxicity of amyloid beta peptide by impeding its ordered aggregation. J Biol Chem. 286:4248–4256. 2011. View Article : Google Scholar : PubMed/NCBI
19	Egaña JT, Zambrano C, Nuñez MT, Gonzalez-Billault C and Maccioni RB: Iron-induced oxidative stress modify tau phosphorylation patterns in hippocampal cell cultures. Biometals. 16:215–223. 2003. View Article : Google Scholar : PubMed/NCBI
20	Ayton S, Faux NG and Bush AI: Association of cerebrospinal fluid ferritin level with preclinical cognitive decline in APOE-ε4 carriers. JAMA Neurol. 74:122–125. 2017. View Article : Google Scholar : PubMed/NCBI
21	Haacke EM, Makki M, Ge Y, Maheshwari M, Sehgal V, Hu J, Selvan M, Wu Z, Latif Z, Xuan Y, et al: Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. J Magn Reson Imaging. 29:537–544. 2009. View Article : Google Scholar : PubMed/NCBI
22	Schiepers OJ, van Boxtel MP, de Groot RH, Jolles J, de Kort WL, Swinkels DW, Kok FJ, Verhoef P and Durga J: Serum iron parameters, HFE C282Y genotype, and cognitive performance in older adults: Results from the FACIT study. J Gerontol A Biol Med Sci. 65:1312–1321. 2010. View Article : Google Scholar
23	Milward EA, Bruce DG, Knuiman MW, Divitini ML, Cole M, Inderjeeth CA, Clarnette RM, Maier G, Jablensky A and Olynyk JK: A cross-sectional community study of serum iron measures and cognitive status in older adults. J Alzheimers Dis. 20:617–623. 2010. View Article : Google Scholar : PubMed/NCBI
24	Wang ZX, Tan L, Wang HF, Ma J, Liu J, Tan MS, Sun JH, Zhu XC, Jiang T and Yu JT: Serum iron, zinc, and copper levels in patients with Alzheimer's disease: A replication study and meta-analyses. J Alzheimers Dis. 47:565–581. 2015. View Article : Google Scholar : PubMed/NCBI
25	House MJ, St Pierre TG, Milward EA, Bruce DG and Olynyk JK: Relationship between brain R(2) and liver and serum iron concentrations in elder men. Magn Reson Med. 63:275–281. 2010. View Article : Google Scholar : PubMed/NCBI
26	Lin D, Ding J, Liu JY, He YF, Dai Z, Chen CZ, Cheng WZ, Zhou J and Wang X: Decreased serum hepcidin concentration correlates with brain iron deposition in patients with HBV-related cirrhosis. PLoS One. 8:e655512013. View Article : Google Scholar : PubMed/NCBI